RxDoctor Payments Data

Melchor Sipalay, MD

Internal Medicine · Pueblo, CONPI 1356390074

Payments from drug & device makers

$4,320in general payments, 2019–2025

Across 258 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$632
  • Novo Nordisk$561
  • Pfizer$411
  • Johnson & Johnson$281
  • Lilly USA, LLC$277
  • AbbVie$271
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$4,320100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,320 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$298,724
Medicare patients
493
Services billed
13,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$128,365
OzempicSemaglutide82$105,742
JardianceEmpagliflozin71$73,208
TrulicityDulaglutide39$58,803
JanuviaSitagliptin Phosphate47$52,893
FarxigaDapagliflozin Propanediol26$25,702
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$24,036
Tresiba Flextouch U-100Insulin Degludec41$19,048
XareltoRivaroxaban27$18,704
Breo ElliptaFluticasone/Vilanterol16$17,519
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,703
SymbicortBudesonide/Formoterol Fumarate21$10,376
ShingrixVaricella-Zoster Ge/As01b/Pf42$9,245
Levothyroxine Sodium540$5,831
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$5,661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$411$132,409127 claims
Novo NordiskOzempic$561$105,74282 claims
Boehringer IngelheimJardiance$133$73,20871 claims
Lilly USA, LLCTrulicity$277$58,80339 claims
MerckJanuvia$60$52,89347 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$103$50,80079 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$632$46,78158 claims
Johnson & JohnsonXarelto$281$18,70427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →